Tjalf Ziemssen

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

J William L Brown, Alasdair Coles, Dana Horáková et al. · JAMA · 2019 · 511 citations · Full text

Stroke-Induced Immunodepression

Ulrich Dirnagl, Juliane Klehmet, Johann Braun et al. · Stroke · 2007 · 451 citations

Inflammation, Ischemic Stroke, Medicine +11

Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid

Christian Schläger, Henrike Körner, Martin Krueger et al. · Nature · 2016 · 353 citations · Full text

Neuroanatomy, Medicine, Cerebrospinal Fluid +12

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8